Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Maryland
We hypothesize that the use of the LLA bupivacaine will promote local inflammation leading to increased pain and central sensitization as evaluated by increase in pain at later time points. Hence our main hypothesis to be evaluated and statistically tested for our primary endpoint (Aim 1) is:
HO: There is no difference in mean levels of biochemical mediators of inflammation between groups.
HA: The bupivacaine group has higher levels of biochemical mediators following surgery.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female volunteers referred for endodontic surgery willing to undergo 2 visits: 1 surgical appointment, and 1 follow-up research-related appointment
Ages of 18 and older
Willing to undergo observation for 1/2 hour post-operatively
Willing to complete a 100 mm visual analog scale and record analgesic intake over 48 hrs period
Willing to have a preoperative and postoperative biopsy on the day of surgery
Willing to return at 48 hours post-operation to turn in completed pain diaries and for the third biopsy
You may not be if
Allergy to or other contraindications to use of aspirin, sulfites, amide anesthetics, or acetaminophen
Chronic use of medications confounding the assessment of the inflammatory response or analgesia, for example, NSAIDS, COX-2 inhibitors, antihistamines, steroids, antidepressants
Medications contraindicated with bupivacaine: MAO inhibitors and anti-depressants
Diseases such as diabetes mellitus, liver disease, chronic infections, rheumatoid arthritis or any other systemic disease that compromises the immune system
Unusual surgical difficulty
Clareo Health | Bupivacaine Versus Lidocaine on Inflammatory Regulation
